Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Solid Tumor 1Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Imatinib Mesylate 66Mercaptopurine 65Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia × LY2510924 × Clear all
NCT02652871 2019-11-15

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡